## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed purcuant to Section 16(a) of the Securities Exchange Act of 1024

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response.	05									

			tu pursuarii iu Seciiuri 10(a) ur irie Securries Excriariye Aci ur 1934			
()			or Section 30(h) of the Investment Company Act of 1940			
1. Name and Address of Reporting Person <sup>*</sup> <u>Malik Rajesh</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>G1 Therapeutics, Inc.</u> [ GTHX ]		ationship of Reporting Pe k all applicable) Director	10% Owner
DR.		(Middle) 79 TW ALEXANDER NS, SUITE 100	3. Date of Earliest Transaction (Month/Day/Year)   12/17/2018		Officer (give title below) Ch. Medical Officer	Other (specify below)
(Street) RESEARCH TRIANGLE PARK (City)	NC (State)	27709 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line) X	vidual or Joint/Group Filir Form filed by One Re Form filed by More the Person	porting Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	12/17/2018		M <sup>(1)</sup>		3,776	A	\$4.17	18,476	D	
Common Stock	12/17/2018		S <sup>(1)</sup>		3,776	D	\$30	14,700	D	

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$4.17	12/17/2018		<b>M</b> <sup>(1)</sup>			3,776	(2)	05/10/2026	Common Stock	3,776	\$0.00	65,519	D	

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

2. The shares underlying this option vested as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

**Remarks:** 

/s/ James Stillman Hanson, attorney-in-fact

12/17/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.